Table 4.

Outcomes at 1 year.

	Unadjusted			Adjusted
	Adverse employment change (n=492)	No adverse change (n=4238)	P value	HR (95% CI)
PHQ2 depression score >3	27.4%	16.7%	<0.001	1.60 (1.27, 2.02)
EQ5D Visual Analog Scale	73 (17.8)	78 (14.8)	<0.001	−3.23 (−4.73, −1.74)*
Medication adherence	68.0%	70.6%	0.226	1.15 (0.93, 1.41)
Medication persistence
• P2Y12 inhibitors	86.1%	88.2%	0.185	0.88 (0.68, 1.14)
• Aspirin	95.3%	96.3%	0.239	0.86 (0.53, 1.40)
• Statins	86.1%	88.3%	0.178	0.87 (0.67, 1.13)
• Beta-blockers	86.0%	87.0%	0.565	0.91 (0.70, 1.17)
• ACEi/ARB	78.0	81.4%	0.116	0.80 (0.63, 1.02)
Moderate/extreme financial hardship with medication costs	41.0%	28.4%	<0.001	1.57 (1.33, 1.87)

Continuous variables expressed as mean (standard deviation). Adjusted for age, sex, race, BMI, MI type, prior MI, diabetes, hypertension, smoking, unplanned rehospitalizations in first year, BARC 2+ bleeding in first year, number of medications reported at 1 year, baseline EQ5D VAS, baseline PHQ2. *Linear regression results expressed as estimate (95% CI)

Abbreviations: ACEi – angiotensin converting enzymes inhibitor, ARB – angiotensin receptor blocker, CI – confidence interval, HR – hazard ratio